As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.
At the 2025 Society for Neuroscience meeting, scientists discussed the adverse side effects of GLP-1 agonists and new ...
People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their cells into tiny factories churning out a protein that is essentially the active ...
Futurism on MSN
Scientists Say They’ve Figured Out a Way to Reprogram the Pancreas to Produce GLP-1s Without Ozempic
Scientists say they've come up with a way for the body to produce its own store of glucagon-like peptide-1 (GLP-1).
New research from Osaka Metropolitan University finds that black cumin, a common kitchen spice, can lower cholesterol, reduce ...
Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways ...
Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...
Chong Kun Dang announced on the 10th that it recently presented research achievements from its oncology and metabolic disease pipelines at poster ...
Insilico announced the launch of its innovative cardiometabolic disease portfolio at BIO Europe 2025. The portfolio covers a range of diverse mechanisms and stages from early discovery to preclinical ...
Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.
Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM ESTCompany ParticipantsStephan Tanda - President, CEO ...
Khanani MD, MA, FASRS, Sierra Eye Associates in Reno, NV, for an overview of the preclinical pharmacology and toxicology studies that underpin the program’s novel platform, the IND‑enabling package ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback